Given that residual levels of FMRP expression explain in part the heterogeneity in the FXS phenotype, the integration of diagnostic genomic data with FMR1 mRNA measuring assays and more accurate FMRP profiles could clarify the relationships between genotypes, mRNA/protein expression and patient phenotypes. The gene discussed is FMR1; the disease is fragile X syndrome.